newly diagnosed transplant ineligible multiple myeloma
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Patients) The study population are those who meet all of the following items: 1.Patients who are aged 18 years or older at the time of informed consent. 2.Patients who diagnosed as multiple myeloma, started induction therapy without transplantation, are currently under observation, or have stable disease status. 3.Patients who have agreed to participate in the survey questionnaire (Doctors) The study population are those who meet all of the following items: 1.Hematologists who are affiliated with hospitals 2.Doctors who have diagnosed two or more cases of multiple myeloma annually 3.Doctors who have agreed to participate in the survey questionnaire
Exclusion criteria
Exclusion criteria: (Patients) 1.Patients who cannot complete responses to the questionnaire (Doctors) No settings
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the current state of patient-physician communication in the treatment of NDMM both at the start of treatment and after disease control. | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify changes in patients' knowledge, mental status, values, treatment goals, and preferences regarding treatment decisions at the start of treatment and after disease control. | — |
Countries
Japan
Contacts
Public ContactYuta Okamura
Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit
Outcome results
None listed